---
title: "TRDA.US (TRDA.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TRDA.US/news.md"
symbol: "TRDA.US"
name: "TRDA.US"
parent: "https://longbridge.com/en/quote/TRDA.US.md"
datetime: "2026-03-08T06:31:08.844Z"
locales:
  - [en](https://longbridge.com/en/quote/TRDA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TRDA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TRDA.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/TRDA.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/TRDA.US/news.md)


# TRDA.US (TRDA.US) — Related News

### [Entrada Therapeutics announces grants under Nasdaq rule 5635(c)(4) for new employees.](https://longbridge.com/en/news/277523455.md)
*2026-03-02T21:31:45.000Z*
> Entrada Therapeutics has announced grants under Nasdaq rule 5635(c)(4) for new employees, indicating a strategic move to

### [Earnings Summary: Entrada Therapeutics Q4](https://longbridge.com/en/news/277041232.md)
*2026-02-26T12:26:13.000Z*
> Entrada Therapeutics (NASDAQ:TRDA) reported Q4 earnings on February 26, 2026, beating estimates by 22.95% with an EPS of

### [Entrada Therapeutics | 10-K: FY2025 Revenue Misses Estimate at USD 25.42 M](https://longbridge.com/en/news/277037613.md)
*2026-02-26T12:11:57.000Z*
### [Entrada Therapeutics | 8-K: FY2025 Q4 Revenue Misses Estimate at USD 1.299 M](https://longbridge.com/en/news/277036391.md)
*2026-02-26T12:06:03.000Z*
### [Roth MKM Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)](https://longbridge.com/en/news/276195208.md)
*2026-02-18T03:55:16.000Z*
> Roth MKM analyst Boobalan Pachaiyappan has maintained a Buy rating on Entrada Therapeutics Inc (TRDA) with a price targe

### [Entrada Therapeutics Inc On Track To Report Elevate-44-201 Cohort 1 Data In Q2 2026, Cohort 2 Data By End Of Year](https://longbridge.com/en/news/276123268.md)
*2026-02-17T12:27:46.000Z*
> Feb 17 (Reuters) - Entrada Therapeutics Inc:* ENTRADA THERAPEUTICS INC - ON TRACK TO REPORT ELEVATE-44-201 COHORT 1 DATA

### [Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit](https://longbridge.com/en/news/276012131.md)
*2026-02-15T20:02:51.000Z*
> Entrada Therapeutics (NASDAQ:TRDA) presented at the Guggenheim 2026 Emerging Outlook Biotech Summit, highlighting its fo

### [Entrada Therapeutics (NASDAQ:TRDA) Raised to Strong-Buy at Guggenheim](https://longbridge.com/en/news/275894075.md)
*2026-02-13T11:45:29.000Z*
> Guggenheim has upgraded Entrada Therapeutics (NASDAQ:TRDA) to a "strong-buy" rating in a recent research report. The sto